Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET
Company Participants
Lisa Miller - Vice President, Investor Relations
Rick Hawkins - Chief Executive Officer and Chairman
John McKew - President and Chief Scientific Officer
Lori Lawley - Chief Financial Officer
Duke Pitukcheewanont - Chief Medical Officer
Conference Call Participants
Catherine Novack - Jones Trading
Leland Gershell - Oppenheimer
Charles Duncan - Cantor Fitzgerald
Operator
Good afternoon and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Programs Update Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference is being recorded.
I will now turn the call over to Lisa Miller, Vice President of Investor Relations.
Lisa Miller
Thank you, Operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under US Federal Securities Laws.
These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.
The forward-looking looking statements made during this call can speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements.
Information presented on this call is contained in the press release we issued this afternoon and in our Form 10-Q and 8-K, which may be accessed from the Investors page of the Lumos Pharma website.
Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, President and Chief Scientific Officer; and Lori Lawley, Chief Financial Officer. Dr. Duke Pitukcheewanont, our Chief Medical Officer, will also join the call for the question-and-answer section.
It is now my pleasure to turn the call over to Rick for our opening remarks.
Rick Hawkins
I'm pleased to be speaking with you today to provide an update on our progress advancing LUM-201 as the first oral therapeutic for moderate pediatric growth hormone deficiency or PGHD.
During the second quarter and recent weeks, we've made significant progress in advancing our plans for a Phase 3 pivotal trial of LUM-201 in PGHD. Following a very positive and productive end of Phase 2 meeting with the FDA, we have nearly finalized our proposal for a Phase 3 double-blinded placebo-controlled clinical trial with a 2:1 randomization in approximately 150 patients.